Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Active, not recruiting · NCT01744223 · Registry updated 2022-07-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute myeloid leukemia, bone marrow disorder, graft versus host disease, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, myelodysplastic syndrome, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2022-07-12 | NCT01744223 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bellicum Pharmaceuticals | 12 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baylor Sammons Cancer Center | Dallas | United States | 1 |
| Emory University Winship Cancer Institute | Atlanta | United States | 15 |
| Fred Hutchinson Cancer Research Center | Seattle | United States | 71 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Oregon Health & Science University | Portland | United States | 261 |
| Roswell Park Cancer Institute | Buffalo | United States | 382 |
| University Hospitals of Cleveland | Cleveland | United States | 17 |
| UT Southwestern Medical Center | Dallas | United States | 210 |